​

Fate Therapeutics (FATE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

FATE Stock Forecast

Fate Therapeutics (FATE) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $5.00, with a high of $5.00 and a low of $5.00. This represents a 281.68% increase from the last price of $1.31.

$1 $2 $3 $4 $5 $6 $7 $8 High: $5 Avg: $5 Low: $5 Last Closed Price: $1.31

FATE Stock Rating

Fate Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (45.45%), 5 Hold (45.45%), 1 Sell (9.09%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 5 5 Strong Sell Sell Hold Buy Strong Buy

FATE Forecast vs Benchmarks

TypeNameUpside
StockFate Therapeutics281.68%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-17
Avg Price Target-$5.00$5.71
Last Closing Price$1.31$1.31$1.31
Upside/Downside-281.68%335.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 252412--18
Dec, 242412--18
Nov, 243412-120
Oct, 2433111119
Sep, 2433111119
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Etzer DaroutBMO Capital$5.00$3.3748.37%281.68%
Aug 14, 2024Benjamin BurnettStifel Nicolaus$5.00$3.2752.91%281.68%
Jun 17, 2024Edward TenthoffPiper Sandler$6.00$3.6166.20%358.02%
May 16, 2024Debjit ChattopadhyayH.C. Wainwright$5.00$4.2417.92%281.68%
May 10, 2024Edward TenthoffPiper Sandler$4.00$3.883.09%205.34%
May 10, 2024Etzer DaroutBMO Capital$6.00$3.8755.04%358.02%
May 10, 2024Bill MaughanCanaccord Genuity$9.00$3.90130.77%587.02%
Jan 09, 2023Goldman Sachs$4.00$4.40-9.09%205.34%
Jan 06, 2023Morgan Stanley$8.00$4.2289.57%510.69%
Jan 06, 2023Piper Sandler$12.00$11.009.09%816.03%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024OppenheimerPerformPerformhold
Nov 13, 2024BMO CapitalMarket PerformMarket Performhold
Aug 14, 2024Cowen & Co.HoldHoldhold
Aug 14, 2024BMO CapitalMarket PerformMarket Performhold
Aug 14, 2024Piper SandlerOverweightOverweighthold
Jun 17, 2024Sandler O'NeillUnderperformUnderperformhold
Jun 17, 2024Piper SandlerNeutralOverweightupgrade
May 16, 2024H.C. WainwrightNeutralNeutralhold
May 10, 2024Piper SandlerNeutralNeutralhold
May 10, 2024BMO CapitalMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.07$-2.18$-2.63$-1.64-----
Avg Forecast$-1.83$-2.21$-3.21$-1.72$-1.63$-1.67$-1.50$-1.33$-1.30
High Forecast$-2.82$-3.40$-4.84$-1.89$-1.90$-2.08$-2.18$-2.07$-1.48
Low Forecast$-1.44$-1.73$-2.66$-1.63$-1.18$-0.81$-1.16$-0.84$-1.11
Surprise %13.11%-1.36%-18.07%-4.65%-----

Revenue Forecast

$0 $20M $40M $60M $80M $100M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$31.43M$55.85M$96.30M$63.53M-----
Avg Forecast$20.58M$50.85M$69.09M$63.40M$13.52M$3.67M$4.14M$14.05M$55.63M
High Forecast$17.15M$42.38M$59.97M$62.73M$12.59M$3.26M$4.05M$12.49M$49.44M
Low Forecast$29.14M$72.00M$96.14M$63.88M$16.05M$4.08M$4.23M$15.61M$61.81M
Surprise %52.74%9.82%39.38%0.22%-----

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-170.30M$-206.30M$-255.06M$-160.93M-----
Avg Forecast$-128.58M$-196.17M$-277.96M$-160.93M$-178.23M$-142.14M$-164.13M$-143.33M$-127.55M
High Forecast$-154.30M$-235.41M$-333.55M$-193.11M$-187.41M$-205.04M$-214.29M$-204.15M$-145.97M
Low Forecast$-102.87M$-156.94M$-222.37M$-128.74M$-116.39M$-79.24M$-113.96M$-82.51M$-109.13M
Surprise %32.44%5.16%-8.24%------

FATE Forecast FAQ

Is Fate Therapeutics stock a buy?

Fate Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Fate Therapeutics is a favorable investment for most analysts.

What is Fate Therapeutics's price target?

Fate Therapeutics's price target, set by 11 Wall Street analysts, averages $5 over the next 12 months. The price target range spans from $5 at the low end to $5 at the high end, suggesting a potential 281.68% change from the previous close price of $1.31.

How does Fate Therapeutics stock forecast compare to the average forecast of its sector, industry, and investment themes?

Fate Therapeutics stock forecast shows a 281.68% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Fate Therapeutics over the past three months?

  • January 2025: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 11.11% Strong Buy, 22.22% Buy, 66.67% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 15.00% Strong Buy, 20.00% Buy, 60.00% Hold, 0% Sell, 5.00% Strong Sell.

What is Fate Therapeutics’s EPS forecast?

Fate Therapeutics's average annual EPS forecast for its fiscal year ending in December is -1.63 for 2024, a -0.61% decrease from the reported $-1.64 in 2023. The prediction for 2025 is $-1.67, $-1.5 for 2026, $-1.33 for 2027, and $-1.3 for 2028.

What is Fate Therapeutics’s revenue forecast?

Fate Therapeutics's average annual revenue forecast for its fiscal year ending in December is $13.52M for 2024, a -78.72% decrease from the reported $63.53M in 2023. The forecast for 2025 is $3.67M, $4.14M for 2026, $14.05M for 2027, and $55.62M for 2028.

What is Fate Therapeutics’s net income forecast?

For its fiscal year ending in December, Fate Therapeutics's average annual net income forecast is $-178M for 2024, reflecting an 10.75% increase from the reported $-161M in 2023. The projection for 2025 is $-142M, $-164M for 2026, $-143M for 2027, and $-128M for 2028.